Tuberculosis Preventive Therapy among Persons Living with HIV, Uganda, 2016-2022

• Published in: Emerging infectious diseases Vol. 29; no. 3; pp. 609 - 613
• Main Authors: Lukoye, Deus, Gustavson, Gail, Namuwenge, Proscovia M, Muchuro, Simon, Birabwa, Estella, Dejene, Seyoum, Ssempiira, Julius, Kalamya, Julius N, Baveewo, Steven, Ferroussier-Davis, Odile, Mills, Lisa A, Dirlikov, Emilio, Nelson, Lisa J, Turyahabwe, Stavia
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01.03.2023; Centers for Disease Control and Prevention
• Subjects: Acquired immune deficiency syndrome; Acquired Immunodeficiency Syndrome; AIDS; bacteria; Care and treatment; COVID-19; Dispatch; Highly active antiretroviral therapy; HIV; HIV (Viruses); HIV Infections - prevention & control; HIV patients; HIV testing; HIV/AIDS and other retroviruses; Human immunodeficiency virus; Humans; Interferon; latent tuberculosis infection; Mass Screening; Medicine, Preventive; Prevention; Preventive health services; respiratory infections; Rifapentine; Statistics; Tuberculosis; Tuberculosis - diagnosis; tuberculosis and other mycobacteria; tuberculosis preventive therapy; Tuberculosis Preventive Therapy among Persons Living with HIV, Uganda, 2016–2022; Uganda; Uganda; United States > US; bacteria; HIV/AIDS and other retroviruses; latent tuberculosis infection; tuberculosis and other mycobacteria; PEPFAR; Uganda; tuberculosis preventive therapy; respiratory infections
• ISSN: 1080-6040; 1080-6059; 1080-6059
• DOI: 10.3201/eid2903.221353

During October 2016-March 2022, Uganda increased tuberculosis (TB) preventive therapy coverage among persons living with HIV from 0.6% to 88.8%. TB notification rates increased from 881.1 to 972.5 per 100,000 persons living with HIV. Timely TB screening, diagnosis, and earlier treatment should remain high priorities for TB/HIV prevention programming.